Closing
Do PCSK9 inhibitors improve quality of life & behaviour versus placebo?
Mostly studied in coronary & atherosclerotic disease. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, the results disagree.
NoUnsureYes
- Belief
- 0.40 (range 0.00–0.55)
- Trials for
- 1
- Trials against
- 1
- Inconclusive
- 0
Already under way
- PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS): Study Protocol for a Multicenter Randomized…NCT06791031 · not yet recruiting · started 2026
- PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary PreventionNCT07581808 · recruiting · started 2026
- Comparative, Randomized, Multicenter, Followed by an Open Label Extension Trial in Patients With a Recent Acute Coronary Syndrome Evaluating the Early…NCT07684469 · not yet recruiting · started 2026
- Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C…NCT06865885 · recruiting · started 2025
- Effectiveness of Inclisiran for Patients With Coronary Heart Disease in China: a Multicenter, Standard of Care-Controlled Pragmatic Randomized TrialNCT06941792 · active not recruiting · started 2025
The evidence so far
- Registered trials
- 18
- With posted results
- 3
- Published papers
- 2
Of 4 decided analyses: 2 favor pcsk9 inhibitors, 2 find no difference, 0 favor the comparator.
Papers
- Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.Meta-analysis / systematic review · 2017
- The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis.Meta-analysis / systematic review · 2021
Trials
- A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) TrialNCT02207634 · 2 posted results
- A Phase IIIb, Multicentre, Randomised Controlled Study to Evaluate the Implementation, Preference and Utility for Administration of Inclisiran Sodium in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD-risk Equivalents and Elevated Low Density Lipoprotein Cholesterol (LDL-C) Using a Primary Care Models in the NHS.NCT04807400 · 4 posted results
- Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and CancerNCT05976893
- Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C LoweringNCT06865885
- PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary PreventionNCT07581808
- Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication RegistryNCT03110432
- "Intensive Lipid-Lowering Therapy Guided by a Cloud-based Software System (CLIMEDO GmbH) in Patients With ST-Elevation and Non-ST-Elevation Myocardial Infarctions" (Germany on Target)NCT05587621
- An Observational Prospective Study to Assess the Effectiveness of Inclisiran(Leqvio®)in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spanish Clinical Practice:the INSPIRE StudyNCT06958315